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Truncated S-MGBs: towards a parasite-specific
and low aggregation chemotype†
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Abedawn I. Khalaf, a Craig Irving,a Kirsten Gillingwater,cd Craig D. Shaw,e
Katharine C. Carter,e Michael P. Barrett,b Colin J. Sucklinga and Fraser J. Scott *a
This paper describes the design and synthesis of Strathclyde minor groove binders (S-MGBs) that have
been truncated by the removal of a pyrrole ring in order to mimic the structure of the natural product,
disgocidine. S-MGBs have been found to be active against many different organisms, however, selective
antiparasitic activity is required. A panel of seven truncated S-MGBs was prepared and the activities exam-
ined against a number of clinically relevant organisms including several bacteria and parasites. The effect of
the truncation strategy on S-MGB aggregation in aqueous environment was also investigated using 1H in-
spection and DOSY experiments. A lead compound, a truncated S-MGB, which possesses significant activ-
ity only against trypanosomes and Leishmania has been identified for further study and was also found to
be less affected by aggregation compared to its full-length analogue.
1. Introduction
Minor groove binders are a class of compound that interact
with the minor groove of DNA. They have been shown to have
a broad range of activities against many biological targets, in-
cluding bacteria, fungi, parasites and cancer cells.1,2 The de-
sign paradigm at the University of Strathclyde has been to
synthesise compounds based loosely upon the structure of
the natural product, distamycin, 1, with antibacterial activity
being at the forefront of compound selection.3 This has
resulted in a lead set of compounds in which the most nota-
ble changes from distamycin are the N-terminal formyl group
being replaced by an aromatic ring, one of the amide links
being replaced by the isosteric alkene, and the replacement of
the amidine with a morpholine, as represented by 2–4.4 These
changes have been based on the desire to minimise toxicity,
modulate lipophilicity and maximise antibacterial activity.
Compounds 2–4 are all significantly active against Gram-
positive bacteria and are in clinical development against both
MRSA and C. difficile, with compound 4 having completed
phase IIa against the latter.5 Although the full mechanism of
antibacterial activity of these compounds has not yet been
established, there is strong evidence that it is novel, involving
the inhibition of several DNA-centric events.6,7
These compounds were selected for development because
of their potent antibacterial properties; however, they also
possess activity against a number of other species, including
various parasites.7–11 This study is concerned with exploiting
the anti-parasitic activity present within this panel of com-
pounds. Activity against multiple organisms presents a poten-
tial issue as our S-MGBs in clinical development exert their
antibacterial effects through a novel mechanism of action and
we may not want to compromise this potential clinical impact
by developing compounds with broad-spectrum activity and a
common mechanism of action in other therapeutic areas.
Consequently, our aim was to identify a different subclass of
S-MGB that did not have antibacterial activity so as to mini-
mise the potential for developing antibacterial resistance if
other S-MGBs were eventually used as antiparasitics. We have
found that whilst DNA binding is necessary for activity, it is
not sufficient, and overall physicochemical properties of
S-MGBs can affect internalization within pathogen cells to a
different extent to afford different pathogen activity pro-
files.6,7 This study thus investigates modifications of the
structures of our lead compound set, without compromising
DNA binding, to remove the antibacterial activity whilst
retaining activity against parasites, namely Trypanosoma
brucei, T. congolense, T. vivax and L. donovani.
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Furthermore, the lead compounds in clinical development
as antibacterial agents require careful formulation due to gela-
tion at concentrations of clinical relevance. Strong anti-parallel
dimerization in dilute aqueous solution has been demonstrated
for alkene-containing MGBs such as 2 and it is this, and further
aggregation, that we believe leads to the undesired gelation.12
Thus, an added consideration in this study is to make structural
changes in order to minimise the self-assembly and conse-
quently mitigating potential solubility issues (Fig. 1).
The S-MGBs in our lead compound set are conceptually
composed of a bis-aromatic alkene head group, two pyrrole
rings and a basic nitrogen containing tail group, all linearly
connected via amide links. Recently, a new natural product,
disgocidine, was identified from Streptomyces netropsis DSM
40846, which also produces distamycin, the compound on
which our S-MGBs are based.13 The structure of disgocidine
matches distamycin exactly, except that it contains one fewer
pyrrole in its structure. Taking inspiration from disgocidine,
for this study, we opted to truncate the length of our S-MGBs
through removing one of the pyrrole rings (Fig. 2).
This truncation strategy would reduce the likelihood of
molecular aggregation by reducing the strength of inter-
molecular dimerization due to fewer intermolecular forces
between dimers. Moreover, these smaller S-MGBs would be
more comparable in design, and overall physicochemical
properties, to the diamidine class of MGBs, a class that are
well-known for their potent antiparasitic activities, such as
furamidine, pentamidine, DB75 or DB289.1,2,7
2. Chemistry
In order to evaluate the truncation strategy, a set of seven
compounds was designed in which the structures explored
several different head groups and tail groups typical of our
S-MGBs. In addition to the morpholine containing tail group
that is common to compounds 2–4, two other tail groups, an
N-methylpiperazine and N,N-dimethylhydrazine, were in-
cluded, to increase the chemical space explored (Fig. 3).
The synthesis of these compounds followed the standard
S-MGB synthesis that has been routinely described. Briefly,
the tail group monomer was constructed by forming the acid
chloride of the nitropyrrole 12 and reacting this with 2 eq. of
either N-methylpiperazine (13), N,N-dimethylhydrazine (14),
or aminoethylmorpholine (15), to form 16, 17 and 18, respec-
tively (Scheme 1). An equivalent of amine was used to quench
the HCl formed during the reaction. The nitro group of the
tail group monomer, 16, 17, or 18, was reduced to the corre-
sponding amine (Pd/C) and subsequently coupled with the
Fig. 1 Structures of distamycin and lead antibacterial S-MGBs.
Fig. 2 Illustration of the truncation strategy.
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previously reported head group carboxylic acids using
HBTU.14 This yielded all the required truncated MGBs, 5–11,
which were purified by HPLC (Scheme 2).
3. Biological activity
The parent compounds have previously been shown to have
significant anti-Gram-positive bacterial activity in addition to
a range of anti-trypanosomal activities.3,7 The newly synthe-
sized compounds were initially evaluated for their anti-
bacterial activity against two strains of Gram-positive bacte-
ria, Staphylococcus aureus, ATCC 43300 and Enterococcus
faecalis, ATCC 51299, and the parasite Trypanosoma brucei
brucei, Lister 427. Vancomycin and diminazene were used as
controls for bacterial and trypanosomal activity, respectively
(Table 1).
The most obvious feature of the activities presented in
Table 1 is the complete loss of antibacterial activity for all of
Fig. 3 Truncated S-MGBs investigated in this study.
Scheme 1 Synthesis of tail group monomers.
























































































RSC Med. Chem. This journal is © The Royal Society of Chemistry 2021
the truncated MGBs; however, the truncation strategy has not
removed all activity. Both compound 10 and compound 11
have retained modest activity against T. b. brucei. This discov-
ery prompted a more detailed investigation of the anti-
parasitic activities of these compounds including an evalua-
tion of activity against two further species of animal
trypanosomes, T. congolense IL3000 and T. vivax STIB719 and
another kinetoplastid parasite, Leishmania donovani, respon-
sible for visceral leishmaniasis in humans. As a measure of
general cytotoxicity, activity against the rat myoblast cell line,
L6 was assessed. Amphotericin B and diminazene were used
respectively as controls for anti-leishmanial and anti-
trypanosomal activity (Table 2).
Compound 11 had an EC50 of 6.6 μM and 6.9 μM against
T. congolense and T. vivax, respectively, which is significant
given its truncated structure. The most interesting compound
of the set is compound 10, which displays approximately an
order of magnitude superior activity against T. congolense and
T. vivax and excellent activity against L. donovani. The activity
of compound 10 against L. donovani with an EC50 of 1.6 is
significant. Using the activity against the L6 cell line as a
measure of mammalian cell toxicity of compound 10 gives se-
lectivity indices of 4.2, 7.7 and 8.2 against L. donovani, T.
congolense and T. vivax, respectively. This level of selectivity is
a positive outcome; however, this compound is not optimised
and understanding from our ongoing S-MGB development
programme could be used to reduce the potential toxicity as
has recently been demonstrated.7
Considering the chemical structures, it is clear that there
exists an important role for the quinoline head group in terms
of the biological activities: both compounds that retain activ-
ity upon truncation contain this head group. Previous studies
have demonstrated that the quinoline head group has a pro-
found effect on enhancing the DNA binding strength of our
full-length S-MGBs.3 Whilst the truncation strategy will have
most likely reduced the DNA binding strength, due to the
smaller molecules having less potential to make favourable
hydrogen bonding or hydrophobic contacts with the minor
groove, those with the quinoline head group, having a higher
binding strength initially, appear to have retained enough
DNA binding to afford activity. To investigate this hypothesis,
a DNA thermal melting study was carried out.
The new truncated compounds. 5–11, along with their par-
ent compounds, 2–4, were evaluated for their relative DNA
binding affinities to a DNA oligomer with base sequence 5′-
GCAAATTTCG-3′ and its complement 5′-CGTTTAAAGC-3′ by
measuring their effects on its melting temperature. The re-
sults are shown in Table 3 below. It is clear from these data
that the truncation of S-MGBs has eliminated DNA binding,
except in those compounds that contain the quinoline head
group. The melting temperature increase difference between
compounds 10 and 11 also indicates the importance of the
tail group in these compounds: the morpholine tail com-
pound, 10, has a 5-fold greater melting temperature increase
compared to the N-methylpiperazine compound, 11. This
may be counter intuitive as 10 possesses the more flexible tail
group, but perhaps this allows for better interaction between
its basic nitrogen and the phosphate backbone.
The development of S-MGBs as selective anti-parasitic
agents, in particular as trypanocides, could be hindered by
Scheme 2 Final coupling to form S-MGBs.
Table 1 In vitro activity of S-MGBs and reference compounds against








2 6.25 25 0.78
3 1.56 3.12 1.56
4 0.2 0.78 <0.19
5 >50 >50 >50
6 >50 >50 >50
7 >50 >50 >50
8 >50 >50 >50
9 >50 >50 >50
10 >50 >50 3.12
11 >50 >50 6.25
Vancomycin 0.39 6.25 —
Diminazene — — 0.5
Table 2 In vitro activity of selected S-MGBs and reference compounds
against L. donovani, T. congolense, T. vivax and L6 rat myoblast cell line




L. donovani T. congolense T. vivax L6
10 1.6 ± 0.90 0.87 ± 0.21 0.76 ± 0.13 6.7 ± 1.1
11 NA 6.6 ± 0.8 6.9 ± 1.2 41 ± 3.1
Amphotericin B 0.10 ± 0.00 — — —
Diminazene — 0.13 ± 0.02 0.17 ± 0.03 —
























































































RSC Med. Chem.This journal is © The Royal Society of Chemistry 2021
cross-resistance to the diamidine class of compounds, which
have been routinely used as antiparasitics for decades, as
these are also thought to function through binding to the mi-
nor groove of DNA.15–17 In our previous study of S-MGBs as
potential agents to treat animal African trypanosomiasis, we
demonstrated that full length S-MGBs did not demonstrate
cross-resistance.7 To assess this risk in these novel truncated
S-MGBS, we tested compounds 10 and 11 on two
diminazene-resistant T. congolense lines selected in vitro. The
same S-MGBs were also tested on two T. b. brucei lines lack-
ing the amino–purine transporter TbAT1/P2,18 which carries
diamidines, and the aquaglyceroporin HAPT1/AQP2,19 known
to be associated with pentamidine uptake in T. brucei, and
whose loss is linked to resistance and cross-resistance onset
in these organisms (Table 4).
The results showed no loss of activity against the
diminazene-resistant T. congolense lines for any of the com-
pounds indicating a lack of cross-resistance. Furthermore, no
changes to EC50 values for the S-MGBs against the T. b. brucei
mutants were observed in the absence of TbAT1/P2 and
HAPT1/AQP2 transporters, confirming that the S-MGBs are
not substrates for these carriers. Taken together, these results
show that the S-MGBs are unlikely to suffer cross-resistance
in parasites resistant to diamidines, despite both classes of
compound binding the minor groove of DNA. This could be
explained by the two classes of compounds entering the cells
via different routes of uptake.
4. Aggregation studies
We know that the propensity for S-MGBs to self-associate can
lead to poor solubility profiles, which is not desirable for any
potential drug. Thus, we sought to use NMR techniques to
obtain an indication of likely solubility issues of a truncated
S-MGB through measuring the degree of self-association.
Compound 10 was selected for this investigation due to its
more favourable activity profile and its full-length analogue,
compound 4, was selected as a reference. As has been ob-
served in previous S-MGBs, both compounds displayed signif-
icant line broadening in an aqueous buffered system (0.1 M
pH 5 sodium acetate) compared to DMSO-d6 – this is indica-
tive of a system involving aggregation (S2†). For 4, this was to
the extent that no signals could be observed. We first sought
to compare this phenomenon between each compound by
systematically acquiring 1H-NMR spectra in a solvent system
with different proportions of DMSO-d6 and pH 5 sodium ace-
tate buffer, using a fixed concentration of 1.5 mM of S-MGB.
Fig. 4 shows an extract of this data focusing on a quinoline
proton in each compound, but the full data sets can be found
in the ESI† (S1–S5 and S7–S11).
For both compounds, there can be seen a change in ppm
of the chemical shift as the proportion of aqueous buffer is
increased. In general, this is an upfield shift, likely caused by
a shielding effect from the π–π stacking of the planar mole-
cules as the aggregate grows. However, the spectrum does ex-
hibit more complex behaviour which could allude to a
change in aggregation behaviour at a critical solvent compo-
sition. The quinoline proton on both 4 and 10 both move up-
field as the proportion of aqueous buffer increases. However,
upon reaching 55% buffer composition, the quinoline proton
of 4, (Fig. 4, panel a), begins to shift downfield. This more
complex behavior was not observed in the truncated MGB,
10, and again could be indicative of an increased aggregation
of 4 relative to 10. Significantly, for the full S-MGB, 4, the
quinoline signals can no longer be observed at 70% v/v
buffer; however, for the truncated S-MGB, 10, the signal can
still be observed in the highest percentage of buffer used in
the experiment (S8†). This difference in behavior is in line
with the truncated S-MGB forming smaller aggregates in
aqueous environments. To confirm this, we also carried out a
comparative DOSY experiment in which we selected a solvent
1q system of 50% v/v pH 5 acetate buffer in DMSO-d6 for a
concentration of 1.5 mM of each S-MGB (Fig. 5). In this
Table 3 DNA melting temperature increase against the oligomer 5′-
GCAAATTTCG′3′/5′-CGTTTAAAGC-3′
S-MGB 2 3 4 5 6 7 8 9 10 11
ΔTm/°C 10 12 20 0 0 0 0 0 10 2
Table 4 In vitro trypanocidal activity of 10 and 11 against two diminazene-resistant T. congolense lines (DimR and EMS MUT DimR) as compared to wild
type (WT) and T. b. brucei lines lacking TbAT1/P2 (tbat1−/−) and TbAT1/P2 plus HAPT1/AQP2 (B48), as compared to wild type (WT) (mean ± SEM, n ≥ 3).
RF, resistance factor
T. congolense EC50 (μM)
Compound WT DimR RF EMS MUT DimR RF
10 3.4 ± 0.4 3.1 ± 0.2 0.9 3.2 ± 0.3 0.9
11 4.3 ± 0.7 4.0 ± 0.9 0.9 4.5 ± 0.6 1.0
Diminazene 0.2 ± 0.01 2.1 ± 0.1 9.5 2.3 ± 0.1 10.9
T. b brucei EC50 (μM)
WT tbat1−/− RF B48 RF
10 1.2 ± 0.03 0.55 ± 0.04 0.5 0.6 ± 0.1 0.5
11 2.7 ± 0.6 2.1 ± 0.6 0.8 2.7 ± 0.6 1.0
Diminazene 0.03 ± 0.01 0.18 ± 0.02 5.9 0.08 ± 0.01 2.6
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Fig. 5 DOSYs of compound 4 (green) and compound 10 (purple).
Fig. 4 a) Structure of compound 4 with a graph of peak shift, relative to the ppm in 80% DMSO-d6/20% 0.1 M pH 5 sodium acetate buffer, of the
quinoline proton marked by an asterisk. b) Structure of compound 10 with a graph of peak shift, relative to the ppm in 80% DMSO-d6/0.1 M 20%
pH 5 sodium acetate buffer, of the quinoline proton marked by an asterisk. c) 1H NMR of a quinoline proton of compound 4 (left) and compound
10 (right). The quinoline proton marked by an asterisk is shown to shift between 9.2–8.4 ppm as the composition of the solvent (DMSO-d6 and 0.1
M pH 5 acetate buffer). The concentration of DMSO-d6 in each sample was diluted by 5% from 80% DMSO-d6, with 0.1 M pH 5 sodium acetate
buffer. A fixed concentration of 1.5 mM of S-MGB 4 or 10 was maintained for each experiment.
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experiment, compound 10 had a diffusion coefficient of
1.753 × 10−10 ± 0.048 × 10−10, whereas the diffusion coeffi-
cient of compound 4 was calculated to be 1.0678 × 10−10 ±
0.0612 × 10−10. This again confirms that the truncation strat-
egy has had the desired effect of reducing the size of S-MGB
aggregates.
5. Conclusion
The purpose of this study was to determine if a truncation
strategy, whereby a pyrrole is removed from the length of an
S-MGB, can reduce antibacterial activity whilst maintaining
activity against parasites. Truncation has been shown to re-
move antibacterial activity, even from compounds that are
highly effective antibacterial therapeutics, and this is likely
due to a combination of a change in physicochemical proper-
ties affecting intracellular accumulation and a reduced affin-
ity for DNA. The reduction in antibacterial activity through
the truncation strategy has not entirely compromised the ac-
tivity against the other organisms under study; moreover,
compound 10 has significant activity against L. donovani and
developable activity against T. congolense and T. vivax. For
these compounds, some DNA binding capability has been
retained, sufficient for activity, and it is likely that the resul-
tant physicochemical properties of the truncated molecules
have not suppressed their ability to enter parasite cells, only
bacterial cells. Furthermore, confirmation was obtained that
no cross-resistance is expected with the diamidine class of
compounds as previous data already indicated.7 We have also
confirmed that the truncation strategy has the added benefi-
cial effect of reducing the extent of S-MGB aggregation in
aqueous environments, likely reducing the potential of prob-
lematic solubility profiles. Compound 10 thus represents a
structure that can be used as a lead for further optimisation
in the design of selective antiparasitic S-MGBs, i.e., those that
do not possess antibacterial activity.
Experimental
Antibacterial assay
The minimum inhibitory concentration (MIC) against S. au-
reus ATCC 43300 and E. faecalis ATCC 51299 was measured
by making two-fold serial dilution of the samples into 96-well
non-binding surface plate (Corning #3640). Bacteria were cul-
tured in cation-adjusted Mueller Hinton broth (CAMHB) over-
night at 37 °C and diluted 40-fold and incubated for a further
1.5–3 h at 37 °C. The resultant mid-log phase cultures were
diluted and added to each well of the compound containing
plates, giving a cell density of 5 × 105 CFU mL−1, measured
by absorbance at 600 nm (OD600), and a final compound
concentration range of 50–0.0195 μM. All the plates were cov-
ered and incubated at 37 °C for 18 h without shaking. Inhibi-
tion of bacterial growth was determined by OD600, using a
Tecan Infinite M Nano plate reader. The percentage of growth
inhibition was calculated for each well, using the negative
control (medium only) and positive control (bacteria without
inhibitors) on the same plate. The MIC was determined as
the lowest concentration at which the growth was fully
inhibited, defined by an inhibition 80%. Each MIC determi-
nation was carried out in triplicate, on separate days.
Anti-Trypanosoma assay
Bloodstream form T. b. brucei (Lister 427) and derived lines
tbat1−/− and B48 were cultured in HMI-11 medium (Gibco)
supplemented with 10% heat inactivated FBS (Gibco), at 37
°C in a humidified 5% CO2 environment. Bloodstream form
T. congolense (strain IL3000) and derived diminazene resistant
lines were cultured at 34 °C in a humidified, 5% CO2 envi-
ronment in MEM medium (Sigma-Aldrich), supplemented
with 25 mM HEPES, 26 mM NaHCO3, 5.6 mM D-glucose, 1
mM sodium pyruvate, 40 μM adenosine, 100 μM hypoxan-
thine, 16.5 μM thymidine and 25 μM bathocuproinedisulfo-
nic acid disodium salt, β-mercaptoethanol (0.0014% v/v), 1.6
mM glutamine, 100 units per ml penicillin, 0.1 mg ml−1
streptomycin, 20% goat serum (Gibco) and 5% Serum Plus
(SAFC Biosciences). Selection of the T. congolense diminazene
resistant lines was carried out as previously described.7 T.
Vivax (STIB 719/ILRAD 560 strain) culture was also carried
out as previously described.20
EC50 values against T. b. brucei and T. congolense were de-
termined by the in vitro Alamar Blue assay. T. b. brucei para-
sites (2 × 104 cells per mL), or T. congolense (2.5 × 105 cells
per mL) were seeded into serial dilutions of the test com-
pounds to a final volume of 200 μl and incubated for 48 h af-
ter which, 20 μL of 0.49 mM resazurin dye (Sigma Aldrich)
was added and cells were incubated for a further 24 h. The
reduction of resazurin was measured using a fluorimeter
(FLUOstar Optima, BMG Labtech) at 544 nm excitation and
590 nm emission wavelengths. EC50 values were determined
using Prism 5 software (GraphPad). All experiments were car-
ried out on at least three independent occasions. EC50 values
against T. vivax were determined using the ex vivo 3H-
hypoxanthine incorporation assay.7
Anti-Leishmania assay
Compounds were screened in vitro for their antileishmanial
activity against the intracellular amastigote stage.21 Bone
marrow derived macrophages (0.5 × 105 cells per well) were
infected using a 20 : 1 host cell : parasite ratio with luciferase-
expressing L. donovani LV82 luc1 (MHOM/ET/67:LV82). The
medium was changed at 24 post-infection to remove free par-
asites and infected cells were treated with medium alone
(controls, n = 6) or doubling dilutions of DMSO (n = 3,
starting at 2% or 2.5% v/v) or MGB compounds (n = 3 or 6,
starting at 25 or 20 μg mL−1, prepared using a 1 mg mL−1
DMSO stock solution). Amphotericin B solution was used as
a positive control and was used at a starting concentration of
1 μM. The medium was removed from each sample at 72
hours post-infection and replaced with 150 μl luciferin solu-
tion (150 μg mL−1 luciferin in serum free medium). The
amount of bioluminescent signal emitted/well was
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determined and used to calculate the mean suppression in
the bioluminescent signal for each test sample compared to
the mean control values. The EC50 values were calculated by
probit analysis.22 The mean EC50 values were calculated from
3 separate experiments.
L6 toxicity assay
To assess the cytotoxicity of tested compounds, the Alamar
Blue assay was followed using the L6 (rat skeletal myoblast)
cell line.7 All experiments were performed in three indepen-
dent assay runs for each compound.
DNA thermal melting study
DNA oligomers and their complements were melted at a rate
of 0.5 °C min−1 in 10 mM PBS buffer solution (pH 7.4) with
50 mM NaCl on a Cary 300 BIO UV-visible spectrophotometer
fitted with a Peltier temperature controller. Programs were
set and data was processed using Cary WinUV software. The
duplex oligomer was made to a concentration of 6 × 10−6 M,
heating to 90 °C and allowed to cool to room temperature
unaided. This was mixed with sufficient S-MGB to give the
appropriate ratio 2 S-MGB : 1 DNA helix. For the reference
melting temperature, no MGB was added. Samples were
heated from 10 °C to 90 °C and cooled from 80 °C to 10 °C
with the spectra being recorded at 260 nm during both of
these cycles. The melting temperatures (Tm) of the duplex
oligomers were determined by fitting a sigmoidal function
using a Boltzmann distribution in OriginPro. This process
was repeated a total of 3 times to ensure repeatability of the
experiment which showed an average error of ±0.5 °C.
Chemical analysis
General experimental methods. 1H and 13C NMR spectra
were measured on a Bruker DPX-500 MHz spectrometer with
chemical shifts given in ppm (d values), relative to proton
and carbon traces in solvent. Coupling constants are reported
in Hz. The data were presented as follows: chemical shift,
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet,
m = multiplet, br = broad, app = apparent), coupling constant
(s) in Hertz (Hz), and integration. Chemical shifts (δ) were
recorded relative to residual DMSO-d6 (δ = 2.50 in
1H NMR
and δ = 35.2 in 13C NMR). IR spectra were recorded on a
Perkin Elmer, 1 FT-IR spectrometer. Mass spectra were
obtained on a Jeol JMS AX505. Anhydrous solvents were
obtained from a Puresolv purification system, from Innova-
tive Technologies, or purchased as such from Aldrich. Melt-
ing points were recorded on a Reichert hot-stage microscope,
and are uncorrected. Chromatography was carried out using
200–400 mesh silica gels, or using reverse-phase HPLC on a
water system using a C18 Luna column and gradient given in
individual entries below. The purity of all new S-MGBs was
greater than 96%, which was confirmed by HPLC.
General tail group monomer synthesis. 1-Methyl-4-nitro-
1H-pyrrole-2-carboxylic acid 12 (100 mg, 0.64 mmol) was
added to thionyl chloride (5 mL) and refluxed for 2 h. The
excess thionyl chloride was then removed under reduced
pressure and the residue dissolved in DCM (5 mL, dry); to
this was added the amine, 13–15 (2.5 equiv.) and then left to
stir for 3 h. The DCM was washed with water (2 × 5 mL) and
the volume of the organic layer was reduced under reduced
pressure and the resulting product was obtained by
filtration.
1-methyl-4-[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]piper-
azine 16. Light brown powder. Yield 80%, mp > 230 °C; IR
(KBr, cm−1): 3375, 3176, 3025, 2496, 2427, 1625, 1588,
1547, 1508, 1461, 1427, 1299; 1H NMR (DMSO-d6, 500
MHz) δ: 8.13 (1H, d, J = 2.0), 6.90 (1H, d, J = 2.0), 3.72 (3H,
s), 3.60 (4H, m), 2.38 (4H, m), 2.23 (3H, s). 13C NMR
(DMSO-d6, 125 MHz) δ: 159.8, 134.0, 126.6, 126.3, 106.3,
54.3, 45.3, 35.9, 30.63. HRMS (FAB) calcd. for C11H17N4O3
[M + H]+, 253.1295; found, 253.1281.
N′,N′,1-Trimethyl-4-nitro-1H-pyrrole-2-carbohydrazide 17.
Light brown powder. Yield 72%, mp > 230 °C; IR (KBr,
cm−1): 3180, 3139, 2835, 2792, 1677, 1651, 1560, 1532, 1494,
1310, 1075; 1H NMR (DMSO-d6, 500 MHz) δ: 10.32 (1H, bs),
8.19 (1H, d, J = 2.0), 7.48 (1H, d, J = 2.0), 3.90 (3H, s), 2.74
(6H, s); 13C NMR (DMSO-d6, 125 MHz) δ: 157.7, 133.8, 128.6,
123.9, 108.5, 46.4, 37.3. HRMS (FAB) calcd. for C8H13N4O3 [M
+ H]+, 213.0982; found, 213.0988.
1-Methyl-N-[2-(4-morpholinyl)ethyl]-4-nitro-1H-pyrrole-2-
carboxamide 18. Light brown powder. Yield 72%, mp 140–
141 °C; IR (KBr, cm−1): 3326, 3118, 2928, 2816, 1634, 1551,
1533, 1146, 1114; 1H NMR (DMSO-d6, 500 MHz) δ: 7.56 (1H,
d, J = 1.9), 7.06 (1H, d, J = 1.9), 6.58 (1H, bs), 4.00 (3H, s),
3.76 (4H, t, J = 4.6), 3.49 (2H, m), 2.59 (2H, t, J = 6.0), 2.51
(4H, t, J = 4.6); 13C NMR (DMSO-d6, 125 MHz) δ: 159.7, 133.7,
127.8, 126.4, 107.2, 66.15, 57.3, 53.2, 37.3, 35.9. HRMS (FAB)
calcd. for C12H19O4N4 [M + H]
+, 283.1406; found, 283.1411.
General truncated S-MGB synthesis
The tail group monomer 16–18 (0.14 mmol) was dissolved in
MeOH (5 mL) and Pd/C-10% was added under nitrogen (15
mg). This was subjected to hydrogenation for 3 h. After this
the solution was filtered through kieselguhr, reduced under
vacuum, and the resultant residue dissolved in DMF (1 mL,
dry). The appropriate carboxylic acid (0.14 mmol) was
dissolved in anhydrous DMF (1 mL), to which was added
HBTU (0.28 mmol) and triethylamine (0.28 mmol) and left to
stir for 30 min. The DMF solution containing the amine was
then added to the that containing the active ester and then
left to stir for 16 h. The reaction mixture was subjected to
HPLC purification to obtain the desired product.
4-[2-({[4-({4-[(E)-2-(3-Methoxyphenyl)ethenyl]benzoyl}amino)-
1-methyl-1H-pyrrol-2-yl]carbonyl}amino)ethyl]morpholin-4-ium
trifluoroacetate 5. Off-white fluffy powder; yield 20%; no distinct
melting point; IR (KBr, cm−1): 3424, 3026, 2928, 2857, 2604,
2483, 1675, 1650, 1606, 1577, 1559, 1536, 1464, 1437, 1402,
1274, 1202, 1131, 1045, 1015; 1H NMR (DMSO-d6, 500 MHz) δ:
10.32 (1H, s), 9.72 (1H, bs), 8.27 (1H, m), 7.96 (2H, d, J = 8.4),
7.74 (2H, d, J = 8.4), 7.31–7.38 (4H, m), 7.21–7.23 (2H, m), 7.03
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(1H, d, J = 1.6), 6.89 (1H, dd, J = 8.0, J = 2.0), 3.95–4.04 (2H, m),
3.86 (3H, s), 3.81 (3H, s), 3.63–3.67 (2H, m), 3.51–3.58 (4H, m),
3.26–3.29 (2H, m), 3.12–3.15 (2H, m); 13C NMR (DMSO-d6, 125
MHz) δ: 163.2, 161.8, 159.6, 158.1, 139.8, 138.1, 133.2, 130.2,
129.7, 127.8, 126.3, 122.3, 122.2, 119.3, 118.8, 113.9, 111.7,
111.6, 104.9, 63.2, 55.6, 55.0, 51.3, 36.1, 33.2. HRMS (FAB) calcd.
for C28H33O4N4 [M + H]
+, 489.2496; found, 489.2496.




trifluoroacetate 6. Off-white fluffy powder; yield 20%; no dis-
tinct melting point; IR (KBr, cm−1): 3271, 2963, 2835, 1666,
1638, 1580, 1439, 1399, 1174, 1127; 1H NMR (DMSO-d6, 500
MHz) δ: 10.32 (1H, s), 10.02 (1H, bs), 8.31 (1H, s), 7.96 (2H, d,
J = 8.4), 7.74 (2H, d, J = 8.4), 7.31–7.38 (4H, m), 7.21–7.23
(2H, m), 7.03 (1H, bs), 6.89 (1H, dd, J = 8.0, J = 2.0), 3.85 (3H,
s), 3.81 (3H, s), 2.80 (6H, s). HRMS (FAB) calcd. for
C24H27O3N4 [M + H]
+, 419.2078; found, 419.2076.




trifluoroacetate 7. Off-white fluffy powder; yield 15%; no dis-
tinct melting point; IR (KBr, cm−1): 3425, 3274, 3026, 2940,
2836, 2722, 2614, 2481, 1677, 1638, 1606, 1575, 1464, 1445,
1413, 1399, 1258, 1201, 1125, 1048, 1026, 1015, 975; 1H NMR
(DMSO-d6, 500 MHz) δ: 10.29 (1H, s), 9.94 (1H, bs), 7.96 (2H,
d, J = 8.4), 7.74 (2H, d, J = 8.4), 7.31–7.38 (4H, m), 7.21–7.23
(2H, m), 6.89 (1H, dd, J = 8.0, J = 2.0), 6.58 (1H, d, J = 1.6),
4.41–4.45 (2H, m), 3.81 (3H, s), 3.70 (3H, s), 3.46–3.49 (2H,
m), 3.27–3.33 (2H, m), 3.07–3.10 (2H, m), 2.84 (3H, s). HRMS
(FAB) calcd. for C27H31O3N4 [M + H]
+, 459.2391; found,
459.2386.




methylhydrazinium trifluoroacetate 8. Orange fluffy powder;
yield 35%; no distinct melting point; IR (KBr, cm−1): 3259,
3100, 3051, 2901, 1699, 1639, 1571, 1564, 1451, 1210, 1120;
1H NMR (DMSO-d6, 500 MHz) δ: 10.28 (1H, s), 9.66 (1H, bs),
9.01 (1H, d, J = 2.0), 8.23 (1H, dd, J = 8.0, J = 2.0), 7.62–7.77
(4H, m), 7.40 (1H, d, J = 1.6), 7.25 (1H, d, J = 16.0), 6.98 (2H,
d, J = 8.0), 6.58 (1H, d, J = 1.6), 4.39–4.50 (2H, m), 3.82 (3H,
s), 3.63 (3H, s), 3.47–3.50 (2H, m), 3.26–3.32 (2H, m), 3.01–
3.11 (2H, m), 2.81 (3H, s). HRMS (FAB) calcd. for C23H25O3N5
[M + H]+, 420.2030; found, 430.2040.




piperazin-4-ium bis(trifluoroacetate) 9. Orange fluffy powder;
yield 15%; no distinct melting point; IR (KBr, cm−1): 3262,
3114, 3051, 2939, 1698, 1668, 1591, 1573, 1446, 1192, 1127;
1H NMR (DMSO-d6, 500 MHz) δ: 10.33 (1H, s), 9.78 (1H, bs),
9.04 (1H, d, J = 2.0), 8.24 (1H, dd, J = 8.0, J = 2.0), 7.63–7.76
(4H, m), 7.35 (1H, d, J = 1.6), 7.24 (1H, d, J = 16.0), 6.99 (2H,
d, J = 8.0), 6.56 (1H, d, J = 1.6), 4.41–4.45 (2H, m), 3.79 (3H,
s), 3.69 (3H, s), 3.46–3.49 (2H, m), 3.27–3.33 (2H, m), 3.07–
3.10 (2H, m), 2.84 (3H, s). HRMS (FAB) calcd. for C26H30O3N5
[M + H]+, 460.2343; found, 460.2340.




ethenyl]quinolinium bis(trifluoroacetate) 10. Yellow fluffy
powder; yield 20%; no distinct melting point; IR (KBr, cm−1):
3414, 2956, 2925, 2851, 2186, 1677, 1651, 1632, 1603, 1533,
1438, 1403, 1389, 1337, 1282, 1204, 1133, 1016; 1H NMR
(DMSO-d6, 500 MHz) δ: 10.37 (1H, s), 9.52 (1H, br), 8.41 (1H,
d, J = 8.5), 8.27 (1H, t, J = 8.0), 7.86–8.02 (8H, m), 7.77 (1H,
m), 7.56–7.66 (2H, m), 7.31 (1H, d, J = 1.7), 7.04 (1H, d, J =
1.7), 3.98–4.03 (2H, m), 3.85 (3H, s), 3.62–3.68 (2H, m), 3.51–
3.59 (4H, m), 3.27 (2H, m), 3.12 (2H, m). HRMS (FAB) calcd.
for C30H32O3N5 [M + H]
+, 510.2500; found, 510.2499.






Time (min) % water (with 0.1% TFA) % MeCN (with 0.1% TFA)
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quinolinium bis(trifluoroacetate) 11. Yellow fluffy powder;
yield 21%; no distinct melting point; IR (KBr, cm−1): 3286,
2870, 2632, 2494, 1679, 1655, 1649, 1565, 1459, 1267, 1181;
1H NMR (DMSO-d6, 500 MHz) δ: 10.34 (1H, s), 9.79 (1H, bs),
9.27 (1H, d, J = 2.0), 8.56 (1H, d, J = 2.0), 7.99–8.06 (4H, m),
7.75–7.84 (3H, m), 7.61–7.71 (3H, m), 7.39 (1H, d, J = 1.6),
6.59 (1H, d, J = 1.6), 4.43–4.47 (2H, m), 3.70 (3H, s), 3.48–3.51
(2H, m), 3.28–3.35 (2H, m), 3.08–3.13 (2H, m), 2.85 (3H, s).
HRMS (FAB) calcd. for C29H30O2N5 [M + H]
+, 480.2394; found,
480.2395.
HPLC procedure: flow rate: 6 mL min−1. Retention time:
14.4 min
NMR aggregation experiments. The NMR techniques used
to investigate the self-association behaviours of S-MGB's 4
and 10 involved obtaining standard 1H-NMRs of each S-MGB
compound in a set variety of solvent system compositions.
The concentration of DMSO-d6 in each sample was diluted by
5% starting from 80% DMSO-d6, with pH 5 sodium acetate
buffer. Thus, twelve spectra for both S-MGB 4 and 10 were
obtained with the following solvent system compositions: (A)
80% DMSO-d6: 20% pH 5 sodium acetate buffer, (B) 75%
DMSO-d6: 25% pH 5 sodium acetate buffer, (C) 70% DMSO-
d6: 30% pH 5 sodium acetate buffer, (D) 65% DMSO-d6: 35%
pH 5 sodium acetate buffer, (E) 60% DMSO-d6: 40% pH 5 so-
dium acetate buffer, (F) 55% DMSO-d6: 45% pH 5 sodium ac-
etate buffer, (G) 50% DMSO-d6: 50% pH 5 sodium acetate
buffer, (H) 45% DMSO-d6: 55% pH 5 sodium acetate buffer,
(I) 40% DMSO-d6: 60% pH 5 sodium acetate buffer, (J) 35%
DMSO-d6: 65% pH 5 sodium acetate buffer, (K) 30% DMSO-
d6: 70% pH 5 sodium acetate buffer, (L) 25% DMSO-d6: 75%
pH 5 sodium acetate buffer. The concentration of both
S-MGB 4 and 10 were fixed at 1.5 mM in each experiment. All
1H-NMR spectral were recorded using a Bruker AVIIIHD
nanobay instrument @ 400 MHz and TopSpin 3.6.2, using
the solvent system compositions specified. Each 1H-NMR ex-
periment was run with 32 scans.
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